Researchers have identified a blood biomarker that predicts the risk of suicide in patients with major depressive disorder. The biomarker also can help researchers understand the molecular changes in suicide victims.
The side effects of administering ketamine to treat major depressive disorder are mild and persist for no longer than four hours, researchers report. Most of the side effects peaked within an hour of treatment, and many patients reported the effects as being significantly reduced two hours post ketamine administration.
People with major depressive disorder who spent more time at home during a two-week period reported more severe symptoms of depression.
A new study of 9/11 first responders helps confirm the link between cognitive impairment and PTSD.
According to researchers, bodily responses to pain are controlled by a neural pathway that involves heightened activity in the spinal cord and two parts of the brain-stem.
Researchers discover some people with major depressive disorder are lacking astrocytes in some hippocampal areas.
Neuroimaging study reveals subtle size differences in the prefrontal region of the brain in young people with major depressive disorders and suicidal behaviors.
For those with treatment resistant depression, a new study reports ECT may not only be the most effective treatment, but also the most cost effective.
The largest genetic map of mental health disorders to date reveals there are three groups of highly genetically related disorders among eight psychiatric disorders. A gene related to nervous system development is a risk factor for all eight disorders studied. The RBFOX1 gene is implicated in seven of the eight disorders. ADHD and depression share 44% of genetic risk factors common in the general population. 109 pleiotropic loci affect more than one disorder. These pleiotropic loci are within genes that show heightened expression in the brain through the lifespan, beginning during the second trimester of pregnancy.